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Long-term follow-up in primary Sjögren’s
syndrome reveals differences in clinical
presentation between female and male
patients
Jorge I. Ramírez Sepúlveda1, Marika Kvarnström1, Per Eriksson2, Thomas Mandl3, Katrine Brække Norheim4,
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Abstract
Background: Despite men being less prone to develop autoimmune diseases, male sex has been associated with a
more severe disease course in several systemic autoimmune diseases. In the present study, we aimed to investigate
differences in the clinical presentation of primary Sjögren’s syndrome (pSS) between the sexes and establish
whether male sex is associated with a more severe form of long-term pSS.
Methods: Our study population included 967 patients with pSS (899 females and 68 males) from Scandinavian
clinical centers. The mean follow-up time (years) was 8.8 ± 7.6 for women and 8.5 ± 6.2 for men (ns). Clinical data
including serological and hematological parameters and glandular and extraglandular manifestations were
compared between men and women.
Results: Male patient serology was characterized by more frequent positivity for anti-Ro/SSA and anti-La/SSB (p = 0.
02), and ANA (p = 0.02). Further, men with pSS were more frequently diagnosed with interstitial lung disease (p = 0.
008), lymphadenopathy (p = 0.04) and lymphoma (p = 0.007). Conversely, concomitant hypothyroidism was more
common among female patients (p = 0.009).
Conclusions: We observe enhanced serological responses and higher frequencies of lymphoma-related
extraglandular manifestations in men with pSS. Notably, lymphoma itself was also significantly more common in
men. These observations may reflect an aggravated immune activation and a more severe pathophysiological state
in male patients with pSS and indicate a personalized managing of the disease due to the influence of the sex of
patients with pSS.
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Background
It has been widely established that women are more
prone to develop autoimmune diseases [1]. Primary
Sjögren’s syndrome (pSS) is a systemic autoimmune dis-
ease characterized by inflammation of the salivary and
lacrimal glands, causing a reduction in exocrine secre-
tion that ultimately leads to the clinical presentation of
sicca symptoms. The reported population-based female
to male ratio is 14:1 [2]. Many hypotheses have been
proposed to explain the overall marked sex bias in auto-
immunity and pSS [3], including genetic and epigenetic
factors [4, 5], sex hormones [6], and X-chromosome ab-
errances [7, 8]. However, the molecular mechanisms that
drive this sex skewing still remain elusive.
Interestingly, the differences between the sexes like-
wise extend to the clinical manifestations, where female
and male patients differ in disease presentation and se-
verity. Despite being less prone to develop autoimmune
diseases, male patients have been reported to have a
more severe disease and a worse prognosis. In systemic
lupus erythematosus (SLE), men present more renal dis-
ease [9] and serositis [10]. Further, Andrade et al. [11]
identified male sex as a strong predictor for poorer long-
term prognosis due to accelerated damage accrual, while
Manger et al. [12] reported male sex as a risk factor for
increased SLE mortality. Male sex is also deemed as a
factor for accelerated disease progression in multiple
sclerosis (MS) [13] and associated with a significantly
higher prevalence of comorbidities [14] such as diabetes,
epilepsy, depression, and anxiety. Although less clear,
sex differences in rheumatoid arthritis (RA) severity and
extra-articular manifestations have also been described;
women appear more prone to present sicca symptoms
and men to have erosive joint disease, rheumatoid nod-
ules, and interstitial lung disease [15, 16].
Regarding pSS, several studies have addressed sex differ-
ences in clinical presentation [17, 18]. As reviewed by
Brandt et al. [3], some authors have identified differences in
extraglandular manifestations and serological markers, with
a focus on female prevalence. However, there is no clear
consensus on whether male sex is associated with a more
severe disease. Our group has described that at diagnosis,
male patients more frequently present with extraglandular
manifestations, more concomitant extraglandular manifes-
tations, and higher anti-Ro52 levels by investigation in two
independent cohorts [19]. To understand if there are sex
differences in the clinical presentation of pSS also after a
long-standing disease and whether risk for comorbidities
vary between the sexes, we assessed glandular and extra-
glandular manifestations, serological parameters, and co-
morbidities of pSS in men and women years after diagnosis
in a large Scandinavian cohort.
Methods
Patients
DISSECT—“Dissecting disease mechanisms in three sys-
temic inflammatory autoimmune diseases with an inter-
feron signature”—is a multicenter consortium comprising
the Scandinavian Sjögren’s syndrome research network,
the Swedish SLE network and the Swedish Myositis net-
work linked to the European Myositis network. All 967
patients with pSS and fulfilling the American–European
consensus criteria [20] in the DISSECT cohort were in-
cluded in this study. Out of these, 899 were females and
68 were males (Table 1). The patients were diagnosed and
followed at the Departments of Rheumatology at the Uni-
versity Hospitals in Gothenburg, Skåne, Linköping,
Örebro, and Uppsala, as well as the Karolinska University
Hospital in Stockholm, Sweden, and the Department of
Rheumatology at Haukeland University Hospital, Bergen,
and the University Hospital in Stavanger, Norway. Of the
205 patients from the Karolinska University Hospital, 127
were included in a previous analysis of clinical manifesta-
tions in female and male patients at diagnosis [19].
Table 1 Demographic and basic characteristics of the cohort
Women n = 899% (frequency) Men n = 68% (frequency) p value
Basic characteristics
Sex 93% (899/967) 7% (68/967) <0.0001
Age at symptom onset (years, mean ± SD) 46.16 ± 14.79 47.88 ± 14.71 0.50
Age at diagnosis (years, mean ± SD) 52.65 ± 13.75 52.63 ± 13.52 0.96
Follow-up time from diagnosis (years, mean ± SD) 8.76 ± 7.62 8.48 ± 6.15 0.68
Item IV. Histopathologya
Salivary gland biopsy
Performed 87% (760/871) 79% (52/66) 0.06
Positive (focus score ≥1) 90% (616/685) 86% (42/49) 0.35
Germinal centers 21% (75/351) 33% (8/24) 0.20
Bold values indicate statistically significant findings (p < 0.05)
aAccording to the 2002 Revised American-European Consensus Group criteria for Sjögren’s syndrome
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Clinical data with regard to autoantibody status and clin-
ical manifestations were retrieved from the patient’s med-
ical records. This included information on sicca symptom
onset, age at diagnosis, histopathological examination of
minor labial salivary gland biopsies, and serological ana-
lysis of ANA, Ro/SSA, and La/SSB autoantibodies. ANA
was determined by indirect immunoflourescence of Hep2
cells for the vast majority of patients, while methods for
determining Ro/SSA and La/SSB autoantibodies at the re-
spective accredited Clinical Immunology department var-
ied over time and between the centers and included
indirect immunofluorescence of transfected cells, im-
munoblotting, ELISA, and multiplex technologies. Infor-
mation on extraglandular manifestations according to
doctors’ clinical assessments included articular, pulmon-
ary, renal, cutaneous, muscular, endocrine, and lymphoid
systems. The study was approved by the local ethical com-
mittee for respective study center, and patients gave in-
formed written consent.
Statistical analysis
For the comparison of continuous variables, the Mann–
Whitney U test was used. The chi-square test was used
when analyzing categorical data, and Fisher’s exact test
was employed if the observed frequency of any given cell
was <5 and/or the total number of analyzed individuals
in any group was <40. Data was analyzed with GraphPad
Prism 6, and p values <0.05 were considered statistically
significant.
Results
Basic characteristics of the cohort
The cohort consisted of 967 pSS patients, of which 899
were women (93%) and 68 were men (7%) (Table 1). The
female/male ratio was 13:1. The mean age at symptom
onset for the female group was 46 years ± 14.8 (95% CI)
and 48 years ± 14.7 (95% CI) for the male group. There
was no significant difference with regard to the age at
diagnosis between women and men (52.6 and 52.6 years,
respectively), or the follow-up time from diagnosis be-
tween female and male patients (8.8 years ± 7.6, 95% CI
and 8.5 years ± 6.1, 95% CI, respectively).
We also compared the histopathological parameters of
the salivary gland biopsy from all the included patients
(Table 1). Although women tended to more frequently
undergo a salivary gland biopsy than men (p = 0.06), the
histological findings revealed no significant differences
in terms of a positive focus score or presence of germi-
nal center-like structures.
Serological differences between female and male patients
with pSS
Autoantibody profiles were also analyzed in a sex-
specific manner (Table 2). Autoantibody positivity was
defined as presenting both or either of anti-Ro/SSA or
anti-La/SSB. Accordingly, 72% of the patients from this
cohort were autoantibody positive; 71% of the female
and 81% of the male patients had either Ro/SSA and/or
La/SSB antibodies.
Anti-Ro/SSA positivity was observed in 68% of the
women and 76% of the men; SSB autoantibodies were
detected in 41% of the women and 57% of the men
(p = 0.01) and positivity for both anti-Ro/SSA and anti-
La/SSB was found in 38% of the women and 52% of the
men (p = 0.02) (Table 2). Furthermore, ANA positivity
was significantly more frequent in male patients
(p = 0.02). Thus, the stratified analysis indicated that the
male group presents significantly higher frequencies of
positivity towards ANA, La/SSB, and Ro/SSA + La/SSB.
Sex hormones have been suggested to influence the
immune system, especially in terms of antibody produc-
tion [21]. To evaluate whether the number or percentage
of autoantibody positive individuals diagnosed was re-
lated to menopause, we further stratified the female and
male patients with and without autoantibodies based on
age at diagnosis (Fig. 1). We observed an increasing
number of autoantibody-positive women being diag-
nosed up to 60 years of age, and that at the same time, a
steadily increasing number of autoantibody negative
women receiving the diagnosis (Fig. 1a). The male group
displayed a comparable pattern (Fig. 1b). Consistently,
also when analyzed as percent autoantibody positive
(Fig. 1c), the trend was similar in both the female and
male groups. Already in the late thirties/early forties the
Table 2 Serological characteristics in female and male patients with pSS
Women n = 899% (frequency) Men n = 68% (frequency) p value
Item VI.a Autoantibodies
Ro/SSA and/or La/SSB positive 71% (640/899) 81% (54/67) 0.1
Ro/SSA positive 68% (612/897) 76% (51/67) 0.18
La/SSB positive 41% (367/894) 57% (38/67) 0.01
Ro/SSA and La/SSB positive 38% (342/892) 52% (35/67) 0.02
ANA positive 74% (660/895) 87% (58/67) 0.02
Italicized values indicate statistically significant findings (p < 0.05)
aAccording to the 2002 Revised American-European Consensus Group criteria for Sjögren’s syndrome
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percentage of autoantibody-positive patients diagnosed
with pSS started to decline and did so steadily until the
mid-seventies. Very few males were diagnosed after the
age of 75 (n = 2), making the last point of the curve less
relevant to consider. Altogether, the data show a consist-
ent higher percentage of autoantibody-positive men.
Neither the female nor male group did show any obvious
change specific for age 50 or 55, which is commonly
used as a proxy for menopause.
Frequencies of clinical manifestations differ between
female and male pSS patients
The presence and type of extraglandular manifestations
were obtained in order to evaluate differences in frequen-
cies among the sexes. There were significant sex differ-
ences in the frequencies of several extraglandular
manifestations (Table 3). Interstitial lung disease was more
frequent in male patients (p = 0.008), as well as lymph-
adenopathy (p = 0.04) and, notably, lymphoma
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Fig. 1 Ro/SSA- and/or La/SSB-positive and negative women and men diagnosed with Sjögren’s syndrome at different age intervals. a Number
of Ro/SSA- and/or La/SSB-positive and negative women diagnosed with Sjögren’s syndrome. b Number of Ro/SSA and/or La/SSB positive and
negative men diagnosed with Sjögren’s syndrome. c Percentage of Ro/SSA and/or La/SSB positive women and men diagnosed with
Sjögren’s syndrome
Ramírez Sepúlveda et al. Biology of Sex Differences  (2017) 8:25 Page 4 of 9
(p = 0.007). There was also a tendency for men to present
more often with major salivary glands swelling (p = 0.11),
as well as myositis (p = 0.14), while hypothyroidism was
more common in female patients, present in 24% of the
women as opposed to 8% of the male patients (p = 0.009).
Considering the observation that men with pSS
present an increased risk for lymphoma when compared
to women (Table 3), we analyzed the difference between
histopathologically verified subtypes of lymphoma.
Mucosa-associated lymphoid tissue (MALT) lymphoma
and diffuse large B cell lymphoma (DLBCL) were the
most common subtypes, but no significant difference be-
tween the occurrence between women and men was
found (Table 4).
Table 3 Frequency of pSS-associated clinical manifestations and comorbidities in female and male patients with pSS
Women n = 899% (frequency) Men n = 68% (frequency) p value
Classificationa
Articular
Arthritis 20% (169/859) 14% (9/65) 0.25
Pulmonary
Interstitial lung disease 6% (40/619) 17% (8/48) 0.008
Renal
Interstitial nephritis 3% (19/607) 2% (1/48) 1.00
Cutaneous
Dermal vasculitis 11% (91/836) 8% (5/62) 0.49
Lymphadenopathy and lymphoma
Enlarged lymph nodes 8% (69/825) 16% (10/62) 0.04
Lymphoma 4% (32/889) 10% (7/68) 0.007
Muscular
Myositis 0.9% (7/772) 3% (2/61) 0.14
Glandular
Major salivary gland swelling 29% (225/767) 40% (21/53) 0.11
Presence of EGM 34% (304/899) 41% (28/68) 0.22
Number of EGM
(mean + SD)
0.44 ± 0.69 0.51 ± 0.74 0.30
Other common comorbidities and clinical manifestations
Hypothyroidism 24% (175/739) 8% (4/51) 0.009
Raynaud’s phenomenon 29% (247/851) 30% (20/66) 0.83
Italicized values indicate statistically significant findings (p < 0.05)
aAvailable data on the extraglandular manifestations evaluated to estimate the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) are included
EGM extraglandular manifestations
Table 4 Frequencies of subtypes of lymphoma in women and men with pSS
Women
n = 32% (frequency)
Men
n = 7% (frequency)
p valuea
MALT lymphoma 56% (18/32) 57% (4/7) 1.00
DLBCL 16% (5/32) 0% (0/7) 0.56
Follicular lymphoma 6% (2/32) 14% (1/7) –
Myeloma 3% (1/32) 0% (0/7) –
CLL 3% (1/32) 0% (0/7) –
Lymphoplasmacytic lymphoma 0% (0/32) 14% (1/7) –
Other NHL 13% (4/32) 14% (1/7) –
Hodgkin lymphoma 3% (1/32) 0% (0/7) –
According to the WHO 2016 classification
aCalculated when n ≥ 5 for either group
MALT mucosa-associated lymphoid tissue, DLBCL diffuse large B cell lymphoma, CLL Chronic lymphatic leukemia, NHL non-Hodgkin lymphoma
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Autoantibody-positive pSS female and male patients
differ in terms of clinical manifestations
We further assessed whether presentation between
autoantibody-positive female and male patients differed
from the unstratified analysis described above, focusing
on the extraglandular manifestations and other clinical
manifestations that had significantly differed between
female and male patients regardless of serology-status.
Interstitial lung disease and lymphoma were significantly
more frequent in men (p = 0.01 and p = 0.03, respect-
ively) also when including only seropositive cases in the
analysis, and hypothyroidism was more common in
women (p = 0.03) (Table 5). Lymphadenopathy had a
higher observed frequency among male patients (Table
3), which was however not statistically significant when
considering only the autoantibody positive cases.
Discussion
Primary Sjögren’s syndrome represents the autoimmune
disease with the highest female bias, ranging from a ratio
of 10–20:1 [22]. Besides the overwhelming sex bias ob-
served in disease susceptibility, previous studies have
also aimed to investigate whether the disease manifests
differently between female and male patients. Earlier
observations have not reached a clear consensus as to
whether male pSS patients have a distinct clinical course
and a more severe presentation of the disease [3]. In a
recent study, though, we reported that men with pSS,
from a population-based incident case cohort, displayed
significantly higher levels of anti-Ro52, were diagnosed
at an earlier age than their female counterparts, pre-
sented more concomitant extraglandular manifestations,
and had a higher frequency of pulmonary complications
and cutaneous vasculitis. Similarly, an Italian cohort re-
vealed a significant male propensity towards extragland-
ular manifestation presentation [19]. These findings
strongly suggest that men affected by pSS have a more
severe disease at time of diagnosis. In the present study,
we addressed whether differences between the sexes are
also present several years after diagnosis.
We identified significant sex differences in terms of
serological parameters and frequencies of some organ in-
volvement. Our results indicate that the humoral response
between women and men is different; particularly, men
present more often with La/SSB, Ro/SSA + La/SSB and
ANA positivity. This increased immune activity observed
among the male patients is of special interest since in a
healthy state, men mount a lower antibody response in
comparison with women [23–25]. Although the patho-
genic effect of autoantibodies has not been clearly estab-
lished, the presence of certain autoantibodies has been
associated with organ manifestations. Noteworthy, SSA
antibodies are related to pulmonary diseases [26, 27], an
extraglandular manifestation we observed overrepresented
in the male patients from our cohort. Further, a recent
study proposed that anti-La/SSB antibodies are a risk fac-
tor associated with increased mortality in pSS patients
[28]. Thus, even though the pathogenic role of pSS-
associated autoantibodies remains unknown, seropositivity
has a strong correlation with organ involvement and
worse prognosis, supporting the conclusion that the dis-
ease course is more severe in male patients than in female
patients.
Interstitial lung disease has been extensively studied in
the context of pSS [29, 30]. Male sex is widely recog-
nized as a risk factor for developing interstitial lung dis-
ease [26, 31]. In accordance with more recent studies
[19], our extended cohort shows that male patients with
pSS are indeed more prone to develop interstitial lung
disease. The reasons for this male preponderance are
poorly understood; however, this might be due to in-
creased seropositivity, environmental exposure to certain
pollutants [32] and smoking [31] in the male pSS group.
In fact, idiopathic pulmonary fibrosis, which represents a
usual interstitial pneumonia histopathological pattern, is
one of the most common forms of interstitial lung dis-
ease detected in pSS [29] and has a higher prevalence in
men, as epidemiological studies have previously
described [33, 34]. In other words, regardless of pSS
diagnosis, men in general are more frequently affected
by a type of interstitial lung disease that is associated
with a worse prognosis. This susceptibility, thus, might
be augmented in pSS, driven by other pathophysiological
factors that enhance this propensity to develop pulmon-
ary disease.
It is well known that pSS patients have an increased
risk for developing non-Hodgkin lymphoma [35–38].
Sex-specific risk for lymphoma development in patients
Table 5 Frequency of comorbidities, extraglandular, and other common clinical manifestations in SSA- and/or SSB-positive female
and male patients with pSS
Women n = 640% (frequency) Men n = 54% (frequency) p value
Interstitial lung disease 7% (31/444) 19% (7/37) 0.01
Enlarged lymph nodes 10% (57/584) 16% (8/49) 0.15
Hypothyroidism 23% (117/517) 8% (3/40) 0.03
Lymphoma 4% (28/634) 11% (6/54) 0.03
Italicized values indicate statistically significant findings (p < 0.05)
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with rheumatic disease has been seldom studied, mainly
due to the inclusion of mostly female patients. Neverthe-
less, Ansell et al. have reported a significantly higher in-
cidence of lymphoma in male RA patients. Despite the
increased association of autoimmune diseases and
lymphoma in men [39], earlier studies of sex differences
in lymphoproliferative malignancies in pSS have not
shown a clear sex-specific predominance [40, 41]. In
contrast, our present study is the largest pSS cohort to
report a significantly increased risk for male patients to
present lymphoma in comparison with female patients.
This is in accordance with the results from a smaller
patient sample from which an increased risk for men
affected with pSS, SLE, RA, and autoimmune hemolytic
anemia to develop lymphoma was reported [42].
Since the male bias observed in pSS-associated malig-
nancies has only recently been described, it is not fully
understood. However, considering the reported predict-
ive factors of lymphoma development, an increased risk
of lymphoma in male patients is logical. As reviewed by
Nocturne and Mariette [43], the main clinical manifesta-
tions and parameters associated with this type of cancer
are swelling of salivary glands, lymphadenopathy, palp-
able purpura, cryoglobulinemia, lymphopenia, low com-
plement levels, and a monoclonal component in serum
or urine. Interestingly, the male pSS patients from our
cohort presented more frequently with lymphadenop-
athy. Although not included in the data analysis due to
the high amount of missing data, cryoglobulinemia was
also more commonly observed in the male patients (20/
151 in females vs 3/7 in males, p = 0.03).
The only clinical manifestation that was more signifi-
cantly represented in the female pSS patients from our
cohort was hypothyroidism. Endocrine problems are not
uncommon in patients with autoimmune disorders [44],
and the female bias towards thyroid diseases has been
extensively documented [45–48]. Furthermore, since the
predominantly female incidence of hypothyroidism cor-
responds with the female susceptibility to autoimmune
diseases, the thyroid gland has been proposed as a de-
cisive organ to explain the sex skewness in autoimmune
diseases. The effect of adipokines, which comprise a
number of different cytokines including, e.g., leptins,
adiponectins, TNF-α, and IL-6, on thyroid tissue has
been suggested as a triggering mechanism for auto-
immune thyroiditis, which probably precedes or coincides
with the diagnosis of another systemic autoimmune dis-
ease such as pSS and SLE. [44]. This emphasizes the need
for a comprehensive screening and close monitoring of
thyroid function in suspected patients because it might be
an important marker for autoimmune disease develop-
ment. As for the thyroid gland being responsible for
female-preponderant diseases, further studies should be
performed to clarify its role.
The studied cohort offers a valuable large group of
clinically carefully characterized patients with pSS,
allowing for analysis of parameters that differ between
men and women affected by the syndrome. The long
follow-up time is essential for identifying clinical mani-
festations at different time points of the disease course.
However, the patients included in this cohort were
mostly included at tertiary referral centers of university
hospital clinics. A possible limitation of the study is that
the study population might therefore not mirror the
general pSS patient population and that the patients
described in this study represent cases with an overall
more severe disease phenotype, both female and male
patients. A further possibility is that male patients with
mild symptoms and less severe disease are less often
referred, as the primary health care doctor may not be
as likely to suspect Sjögren’s syndrome due to its rarity
in men, resulting in only men with more severe disease
being included in the study. As the evaluation of extra-
glandular manifestations was dependent on doctors’ clin-
ical assessments and did not include specific laboratory
or physiologic tests unless the patient had symptoms, it
is also possible that subclinical extraglandular manifesta-
tions may have been missed. However, the mean number
of extraglandular manifestations diagnosed did not differ
significantly between centers, nor did the proportion of
men and women contributed. A further limitation is the
lack of EULAR primary Sjögren’s syndrome disease ac-
tivity (ESSDAI) and patient-reported (ESSPRI) indexes
[49] at diagnosis, as well as information on other com-
mon extraglandular manifestations such as neurological
diseases.
Conclusions
In summary, our findings provide compelling evidence
that the clinical presentation of pSS differs between
women and men. The sex-specific preference of some
clinical manifestations hints at divergent pathophysio-
logical mechanisms between women and men with pSS.
Consequently, management of the disease will benefit
from sex-specific tailored clinical programs to address
complications that are common or expected in the
respective sex.
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